NCT07160608

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Phase 2, Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (I TRANSCEND)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Alexion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Conditions

• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

Type	Name	Description
DRUG	Placebo	Participants will receive placebo.
DRUG	Tarperprumig	Participants will receive tarperprumig.

Timeline

• Start date: 2025-11-26
• Primary completion: 2027-10-11
• Completion: 2028-02-14
• First posted: 2025-09-08
• Last updated: 2026-04-07

Locations

78 sites across 14 countries: Argentina, Australia, Brazil, Canada, China, France, Germany, Italy, Poland, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom

Regulatory

• FDA-regulated drug study